» Articles » PMID: 36212905

Sex Differences in HIV-1 Persistence and the Implications for a Cure

Overview
Specialty Public Health
Date 2022 Oct 10
PMID 36212905
Authors
Affiliations
Soon will be listed here.
Abstract

Of the 38 million people currently living with Human Immunodeficiency Virus type-1 (HIV-1), women, especially adolescents and young women, are disproportionally affected by the HIV-1 pandemic. Acquired immunodeficiency syndrome (AIDS) - related illnesses are the leading cause of death in women of reproductive age worldwide. Although combination antiretroviral therapy (cART) can suppress viral replication, cART is not curative due to the presence of a long-lived viral reservoir that persists despite treatment. Biological sex influences the characteristics of the viral reservoir as well as the immune responses to infection, factors that can have a significant impact on the design and quantification of HIV-1 curative interventions in which women are grossly underrepresented. This mini-review will provide an update on the current understanding of the impact of biological sex on the viral reservoir and will discuss the implications of these differences in the context of the development of potential HIV-1 curative strategies, with a focus on the shock and kill approach to an HIV-1 cure. This mini-review will also highlight the current gaps in the knowledge of sex-based differences in HIV-1 persistence and will speculate on approaches to address them to promote the development of more scalable, effective curative approaches for people living with HIV-1.

Citing Articles

HIV-1 latency reversal and immune enhancing activity of IL-15 is not influenced by sex hormones.

Holmberg C, Levinger C, Abongwa M, Ceriani C, Archin N, Siegel M JCI Insight. 2024; 9(17).

PMID: 39078714 PMC: 11389825. DOI: 10.1172/jci.insight.180609.


Exceptional, naturally occurring HIV-1 control: Insight into a functional cure.

Salgado M, Migueles S, Yu X, Martinez-Picado J Med. 2024; 5(9):1071-1082.

PMID: 39013460 PMC: 11411266. DOI: 10.1016/j.medj.2024.06.008.


Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.

Armani-Tourret M, Bone B, Tan T, Sun W, Bellefroid M, Struyve T Nat Rev Microbiol. 2024; 22(6):328-344.

PMID: 38337034 PMC: 11131351. DOI: 10.1038/s41579-024-01010-8.


HIV-Host Cell Interactions.

Masenga S, Mweene B, Luwaya E, Muchaili L, Chona M, Kirabo A Cells. 2023; 12(10.

PMID: 37408185 PMC: 10216808. DOI: 10.3390/cells12101351.

References
1.
El-Badry E, Macharia G, Claiborne D, Brooks K, Dilernia D, Goepfert P . Better Viral Control despite Higher CD4 T Cell Activation during Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol. J Virol. 2020; 94(16). PMC: 7394904. DOI: 10.1128/JVI.00758-20. View

2.
Stutterheim S, van Dijk M, Wang H, Jonas K . The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis. PLoS One. 2021; 16(12):e0260063. PMC: 8635361. DOI: 10.1371/journal.pone.0260063. View

3.
Yukl S, Kaiser P, Kim P, Telwatte S, Joshi S, Vu M . HIV latency in isolated patient CD4 T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med. 2018; 10(430). PMC: 5959841. DOI: 10.1126/scitranslmed.aap9927. View

4.
Crowell T, Gebo K, Blankson J, Korthuis P, Yehia B, Rutstein R . Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. J Infect Dis. 2014; 211(11):1692-702. PMC: 4447832. DOI: 10.1093/infdis/jiu809. View

5.
Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C . Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013; 9(3):e1003211. PMC: 3597518. DOI: 10.1371/journal.ppat.1003211. View